Study guide

13.2 Acromegaly, Diabetes Insipidus & SIADH

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

13.2 Acromegaly, Diabetes Insipidus & SIADH

Key Takeaways Explain This Topic AI

Acromegaly is confirmed when growth hormone fails to suppress below 1 microgram/L during a 75 g oral glucose tolerance test.

In the water deprivation test, concentration of urine after desmopressin indicates cranial diabetes insipidus, while failure to concentrate indicates nephrogenic disease.

Lithium is the classic drug cause of nephrogenic diabetes insipidus, and demeclocycline is used to treat resistant SIADH.

Last updated: September 2026

  • 3. Acromegaly
  • Etiology & Pathophysiology

Acromegaly is caused by autonomous, chronic hypersecretion of growth hormone (GH), which stimulates hepatic synthesis and systemic secretion of Insulin-like Growth Factor 1 (IGF-1) . More than 99 % 99\% 99% of cases arise from a benign pituitary somatotroph adenoma (macroadenoma in > 75 % > 75\% > 75% ). Rare ectopic sources ( < 1 % < 1\% < 1% ) include neuroendocrine tumors (bronchial or pancreatic carcinoids) hypersecreting GHRH.

Clinical Manifestations

The insidious onset results in an average diagnostic delay of 5 to 10 years:

Somatic & Acral Overgrowth: Enlargement of hands and feet (increasing shoe, ring, and glove sizes), characteristic spade-like fleshy hands with blunt digits, coarse facial features, frontal bossing, prominent supraorbital ridges, prognathism (protruding mandible leading to dental malocclusion and widened teeth spacing), and macroglossia.

Soft Tissue & Metabolic: Severe hyperhidrosis (excessive, pungent greasy sweating due to sweat gland hypertrophy), oily skin, multiple skin tags (acrochordons), obstructive sleep apnoea (OSA in up to 70 % 70\% 70% ), bilateral carpal tunnel syndrome (due to perineural oedema and soft tissue hypertrophy within the carpal tunnel), proximal myopathy, and arthralgia/severe premature osteoarthritis.

Cardiovascular & Endocrine: Systemic hypertension, concentric left ventricular hypertrophy, biventricular diastolic dysfunction, and secondary dilated cardiomyopathy. GH promotes hepatic gluconeogenesis and peripheral insulin resistance, causing impaired glucose tolerance ( 45 % 45\% 45% ) or overt diabetes mellitus ( 25 % 25\% 25% ).

Colorectal Neoplasia: High circulating GH and IGF-1 promote mucosal cellular proliferation; patients have an increased prevalence of adenomatous colonic polyps and colorectal cancer. NICE guidelines mandate baseline screening colonoscopy at age 40 , with ongoing surveillance intervals tailored to polyp findings.

Diagnostic Protocol

First-Line Screening: Serum IGF-1: Unlike pituitary GH (which is pulsatile with a half-life of 20 minutes and easily provoked by stress, sleep, or exercise), serum IGF-1 has a stable circulating half-life and reflects integrated 24-hour GH activity. A normal age- and sex-matched serum IGF-1 robustly excludes acromegaly.

Confirmatory Test: Oral Glucose Tolerance Test (OGTT) with GH Measurement: In healthy individuals, oral glucose ( 75 g 75\text{ g} 75 g ) induces hyperglycaemia that suppresses pituitary GH secretion to < 1.0 mcg/L < 1.0\text{ mcg/L} < 1.0 mcg/L ( < 0.4 mcg/L < 0.4\text{ mcg/L} < 0.4 mcg/L on modern ultrasensitive chemiluminescent assays). In acromegaly, there is failure of GH suppression to < 1.0 mcg/L < 1.0\text{ mcg/L} < 1.0 mcg/L (or a paradoxical rise in GH).

Anatomical Imaging: Pituitary MRI with gadolinium enhancement to define adenoma dimensions and optic chiasm compression; formal Humphrey visual field perimetry.

Therapeutic Strategy

Transsphenoidal Hypophysectomy: First-line definitive treatment of choice. Cures > 80 % > 80\% > 80% of microadenomas and approximately 40 – 50 % 40\text{–}50\% 40 – 50% of macroadenomas.

Medical Therapy (Second-Line / Adjuvant):

Somatostatin Receptor Ligands (SRLs): First-line medical therapy for persistent postoperative disease or poor surgical candidates. Long-acting depot injections administered monthly: Octreotide LAR or Lanreotide Autogel . Bind preferentially to somatostatin receptor subtype 2 (SSTR2), inhibiting GH release and shrinking tumor mass in 50 % 50\% 50% . Adverse effects: Biliary sludge and cholesterol cholelithiasis ( > 25 % > 25\% > 25% ), abdominal cramping, and steatorrhoea. Pasireotide (multi-receptor SRL binding SSTR1, 2, 3, 5) is used for resistant cases but causes profound hyperglycaemia via insulin suppression.

Dopamine Agonists (Cabergoline): Modestly effective; useful in mild disease or mixed GH/prolactin-secreting tumors.

GH Receptor Antagonist (Pegvisomant): Genetically modified analogue of human GH that competitively blocks peripheral GH receptors, preventing hepatic IGF-1 generation. Highly effective at normalizing serum IGF-1 ( > 90 % > 90\% > 90% ), but does not act on the pituitary adenoma (pituitary MRI must be monitored for tumor enlargement, and circulating GH levels rise paradoxical to IGF-1 reduction). Requires regular liver function monitoring due to hepatotoxicity risk.

Stereotactic Radiotherapy (Gamma Knife): Third-line adjuvant therapy for residual or refractory invasive tumors.

  • 4. Diabetes Insipidus (DI) vs SIADH
  • Pathophysiology & Classification of Diabetes Insipidus

Diabetes insipidus is characterized by excretion of large volumes ( > 3 L/24h > 3\text{ L/24h} > 3 L/24h or > 40 – 50 mL/kg/24h > 40\text{–}50\text{ mL/kg/24h} > 40 – 50 mL/kg/24h ) of hypotonic, dilute urine:

Central (Cranial) Diabetes Insipidus: Deficient synthesis or secretion of arginine vasopressin (AVP/ADH) from the posterior pituitary. Causes include idiopathic autoimmune infundibuloneurohypophysitis, pituitary or hypothalamic surgery (classically a triphasic response : initial transient DI [days 1–2], followed by SIADH due to dying axon peptide leakage [days 3–7], culminating in permanent DI [day 8+]), closed head trauma, craniopharyngioma, pinealoma, suprasellar germinoma, Langerhans cell histiocytosis, and sarcoidosis.

Nephrogenic Diabetes Insipidus: Normal or elevated circulating AVP concentrations paired with renal collecting duct resistance to AVP. Causes include:

Pharmacological: Lithium carbonate (downregulates aquaporin-2 water channel transcription via glycogen synthase kinase-3 β \beta β inhibition; develops in up to 20 – 40 % 20\text{–}40\% 20 – 40% of chronic users), demeclocycline, amphotericin B.

Metabolic: Hypercalcaemia (activates calcium-sensing receptors in the thick ascending limb, impairing medullary countercurrent multiplication) and hypokalaemia (impairs collecting duct cAMP generation).

Renal Disease: Chronic tubulointerstitial nephritis, medullary cystic kidney disease, post-obstructive uropathy.

Congenital: X-linked recessive mutations in the vasopressin V2 receptor gene ( A V P R 2 AVPR2 A V PR 2 , 90 % 90\% 90% ), or autosomal mutations in the aquaporin-2 gene ( A Q P 2 AQP2 A QP 2 , 10 % 10\% 10% ).

Water Deprivation (Fluid Deprivation) Test Protocol

The water deprivation test is the cornerstone investigation for polyuria-polydipsia syndromes. Patients must be closely supervised with hourly recordings of body weight, serum osmolality, and urine osmolality:

Phase & Condition Serum Osmolality (mOsm/kg) Urine Osmolality (mOsm/kg) Post-DDAVP Urine Osmolality (mOsm/kg)

Normal Physiology Normal ( 280 – 295 280\text{–}295 280 – 295 ) Concentrates > 750 > 750 > 750 Minimal increase ( < 5 % < 5\% < 5% )

Primary (Psychogenic) Polydipsia Low-normal ( < 280 – 285 < 280\text{–}285 < 280 – 285 ) Concentrates > 500 – 750 > 500\text{–}750 > 500 – 750 (partial medullary washout) Minimal increase ( < 10 % < 10\% < 10% )

Central (Cranial) DI High ( > 295 – 300 > 295\text{–}300 > 295 – 300 ) Fails to concentrate ( < 300 < 300 < 300 ) Marked rise > 50 % > 50\% > 50% (typically > 750 > 750 > 750 )

Nephrogenic DI High ( > 295 – 300 > 295\text{–}300 > 295 – 300 ) Fails to concentrate ( < 300 < 300 < 300 ) Fails to respond ( < 50 % < 50\% < 50% rise, stays < 300 – 400 < 300\text{–}400 < 300 – 400 )

Therapeutic Regimens

Central DI: Treated with the synthetic vasopressin analogue Desmopressin (DDAVP) , administered orally, sublingually, or via nasal spray. Acts selectively on renal V2 receptors with minimal V1 vascular pressor activity.

Nephrogenic DI: Treat underlying electrolyte abnormalities. If lithium-induced, review indication and consider switching; if lithium must be continued, co-administer Amiloride (selectively blocks the epithelial sodium channel [ENaC] in the luminal membrane of principal collecting duct cells, preventing intracellular entry and accumulation of lithium). Paradoxical treatment with thiazide diuretics (e.g. bendroflumethiazide) induces mild volume contraction, triggering compensatory sodium and water reabsorption in the proximal convoluted tubule and decreasing distal fluid delivery to uncollecting ducts. A low-salt, low-protein diet and NSAIDs (e.g. indomethacin, which inhibits renal prostaglandin synthesis that otherwise antagonizes AVP) provide further benefit.